Clinical, economic and societal impact of antibiotic resistance

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 2, 2015, Pages 151-153

  Barriere, Steven L ^a  

^a THERAVANCE INC   (United States)

Author keywords

Antibiotics; Antibiotics in animal feed; Misuse of antibiotics; Resistance

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AVIBACTAM PLUS CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; COLISTIN; PLAZOMICIN; POLYMYXIN B; PREBIOTIC AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CLINICAL PRACTICE; ECONOMIC EVALUATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE INFECTION; HEALTH CARE COST; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORALITY; MORBIDITY; MORTALITY; NONHUMAN; POSTOPERATIVE INFECTION; REVIEW; SOFT TISSUE INFECTION; VETERINARY MEDICINE; ANIMAL; BACTERIAL INFECTIONS; COST; ECONOMICS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COLISTIN; COSTS AND COST ANALYSIS; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 84921033730     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.983077     Document Type: Review

References (18)

1. Fleming A. Penicillin. Nobel Lecture, December 11, 1945
2. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81
3. Dukic VM, Lauderdale DS, Wilder J, et al. Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis. PLoS One 2013;8(1):e52722
4. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century - a clinical super-challenge. N Engl J Med 2009;360:439-43
5. Mathew AG, Cissell R, Liamthong S, et al. Antibiotic resistance in bacteria associated with food animals: a United States perspective of livestock production. Foodborne Pathog Dis 2007;4(2):115-33
6. Casey JA, Curriero FC, Cosgrove SE, et al. High-density livestock production and molecularly characterized MRSA infections in Pennsylvania. JAMA Intern Med 2013;173:1980-90
7. Levy SB. The challenge of antibiotic resistance. Sci Am 1998;3:46-53
8. Mathew AG, Cissell R, Liamthong S. Antibiotic resistance in bacteria associated with food animals: a United States perspective of livestock production. Foodborne Pathog Dis 2007;4:115-33
9. Wegener HC. Antibiotics in animal feed and their role in resistance development. Curr Opin Microbiol 2003;6:439-45
10. Carlet J, Jarlier V, Harbarth S, et al. Participants of the 3rd World Healthcare-Associated Infections Forum. Ready for a world without antibiotics? The pensières antibiotic resistance call to action. Antimicrob Resist Infect Control 2012;1:11
11. Cosgrove SE, Carmeli YA. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;36:1433-7
12. Roberts RR, Hota B, Ahmad I, et al. Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: implications for Antibiotic Stewardship Clin Infect Dis. 2009;49:1175-84
13. Centers for Diseases Control and Prevention, Threat Report, 2013
14. Smith R, Coast J. The true cost of antimicrobial resistance. BMJ 2013;346:f1493
15. Infectious Diseases Society of America. The 10 x '20 Initiative: pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020. Clin Infect Dis 2010;50:1081-3
16. Gilbert DN, Guidos RJ, Boucher HW. Letter to the Editor. Clin Infect Dis 2010;51:754-5
17. Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10 x '20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013;56:1685-94
18. Spellberg B, Blaser M, Guidos RJ, et al. Infectious Diseases Society of America (IDSA). Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011;52(Suppl 5):S397-428